HOW TECH STARTUP FUNDRAISING CHANGED FROM 2005 TO NOW
Modern Biotech Startups is a new rise in 2022 which is changing the whole biotech landscape into a complete transition toward SaaS software compared to VCs method.
VCs preferred to invest in companies that had already demonstrated a good deal of progress towards a viable product.
They prefer to back teams led by people who have previous experience in the tech industry and will not back founders who have no technical experience.
Because they had a lock on the funding market, they asked for onerous financial terms and often replaced founders with favored executives.
The only model of institutional seed funding is the business incubator model, where VC firms fund well-connected founders they know and incubate them in their offices.
But then, the cost to start a tech company fell.
It plummeted because it was replaced by open source software, modern web frameworks, SaaS developer tools, cloud hosting, and better distribution channels.
If you’re a technical founder, this means that a lot of investors will look at your PowerPoint, think they understand how your product will work, and then look for someone else to fund your product.
After they had shown their idea had merit, they were able to secure funding.
Today, companies like this can only need a small amount of money to get started, but there isn’t any place to get it. This is because institutions don’t make small investments anymore.
In this case, the key insight was to focus the company on what mattered and ignore what didn’t.
The rise of the tech startup was driven by easy access to flexible, institutional seed funding that led to an explosion of tech startups. Today, this is the default path for startups to get started.
Because these companies weren’t raising VC until they were much farther along and had leverage, the balance of power shifted.
A significant percentage of founders of early-stage companies are keeping ownership of the company.
Investors lost their ability to fire founders and bring in favored executives.
And when they did, they realized something surprising: despite their lack of experience, the founders were often the right people to run the company.
WHAT’S HAPPENING NOW WITH BIOTECH COMPANIES
The venture creation model is the dominant method used to create high-tech companies today.
A venture capital firm typically creates a company.
They will have an idea and will put together a team of executives, usually from their entrepreneurial community, to run it.
The startup incubates out of the VC’s office.
The VC invests a large amount of money up front and then gives you an equal share.
This model made sense when tech companies were expensive to start, and when the cost to start a biotech company was high.
Because of this infrastructure, bio companies routinely clear major scientific hurdles during the SaaS Biotech program. Often therapeutics companies are able to show that their concept is effective in animal models. Diagnostic companies can show success with human samples. Synthetic biology companies successfully engineer cell lines.
Athelas makes a device that does home blood tests for oncology patients, using a new computer vision-based technique.
The founders of the company, Tanay and Deepika, started their company while they were still in college.
There’s no doubt that running clinical trials is expensive, and biotech companies will eventually need to raise billions of dollars to deliver on their initial promise.
Tech companies are all about innovation.
The best YC (software) companies have raised over $1B in funding.
The important part is that these companies were able to start with less than $100K and to de-risk their idea enough to raise more money later.
PREDICTIONS FOR THE FUTURE OF BIOTECH STARTUPS
It’s possible to start a biotech company cheaply, so it’s now easy to start a biotech company the same way people started a tech company
With a small amount raised at a time, rather than one large payment upfront, you can keep your business under control.
And you can work on your own idea, not just ideas VCs come up with.
If this plays out the way it did in 2005, then we’ll see an explosion in the funding options for biotech companies.
Many traditional biotech investors are still looking for the controlling legal terms that went out of vogue in tech in the early 2000s.
With many biotech and tech/biotech crossover funds having been created, a healthy and vibrant new biotech investor ecosystem has grown.
That’s the result. We now see YC bio companies typically raise $1-5M seed rounds after each batch.
This is great news for biotech investors as it means there’s still a lot more ground to cover for them.
Some of these companies will look more like tech companies: instead of being run by VCs and hired execs, they’ll be run by the founders who care about their ideas and who will sustain that passion by building companies that will change the world for the better.